Please login to the form below

Not currently logged in
Email:
Password:

ado-trastuzumab emtansine

This page shows the latest ado-trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.

Seattle Genetics wins FDA priority review for oral HER2 drug

Seattle Genetics wins FDA priority review for oral HER2 drug

Seattle is seeking approval for tucatinib in combination with Roche’s anti-HER2 antibody (trastuzumab) plus Xeloda (capecitabine). ... ado-trastuzumab emtansine).

Latest news

  • EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

    The EMA has cleared Kadcyla (ado-trastuzumab emtansine) for the adjuvant or post-surgery treatment of adults with HER2-positive early breast cancer, who still have some residual signs of invasive ... cancer cells despite treatment before surgery with

  • Seattle Genetics preps filing next year for oral HER2 drug Seattle Genetics preps filing next year for oral HER2 drug

    The HER2CLIMB trial evaluated tucatinib as an add-on therapy to Roche’s anti-HER2 antibody Herceptin (trastuzumab) plus Xeloda (capecitabine), and it found that the new drug achieved a 46% ... Herceptin plus Xeloda is a standard regimen for

  • Roche preps new Kadcyla filings after phase 3 trial win Roche preps new Kadcyla filings after phase 3 trial win

    In the KATHERINE study, giving Kadcyla (ado-trastuzumab emtansine) to women with residual disease despite pre-surgery (neoadjuvant) therapy significantly reduced invasive disease-free survival or IDFS compared to Herceptin (trastuzumab), ... Meanwhile,

  • Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3 Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

    The Japanese drugmaker’s has started recruiting patients into two pivotal trials of its ADC trastuzumab deruxtecan (DS-8201), one of which will pit the drug against Kadcyla (ado-trastuzumab emtansine) ... in HER2 positive, unresectable and/or

  • NICE relents on Kadcyla after Roche pricing negotiations NICE relents on Kadcyla after Roche pricing negotiations

    The agreement comes after years of wrangling between NICE and the pharma group over the price of Kadcyla (ado-trastuzumab emtansine), which has a list price of £90, 000 a year ... older HER2-targeting drug Herceptin (trastuzumab) with capecitabine that

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics